<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01600404</url>
  </required_header>
  <id_info>
    <org_study_id>2011-25</org_study_id>
    <nct_id>NCT01600404</nct_id>
  </id_info>
  <brief_title>Effects of Antimuscarinics on Cognition in Spinal Cord Injury</brief_title>
  <official_title>Effects of Antimuscarinic Drugs on the Cognition of Patients With Acute Spinal Cord Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Paraplegic Centre Nottwil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Paraplegic Centre Nottwil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective evaluation of the cognitive function of in-house patients suffering from an acute&#xD;
      traumatic spinal cord injury before and three months after the initiation of antimuscarinic&#xD;
      treatment.&#xD;
&#xD;
      The following hypothesis will be tested: Antimuscarinic treatment results in significantly&#xD;
      worse cognitive test results three months after traumatic spinal cord injury compared to the&#xD;
      pre-treatment results and the results of the control group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There will be two groups: 1) patients receiving antimuscarinic treatment 2) patients without&#xD;
      antimuscarinic treatment (control).&#xD;
&#xD;
      The control group will be investigated in order to determine the effects of traumatic spinal&#xD;
      cord injury on cognition and the natural history of potential cognitive impairment within the&#xD;
      first three months after spinal cord injury.&#xD;
&#xD;
      Six to eight weeks after traumatic spinal cord injury, patients are examined in order to&#xD;
      determine the type of neurogenic bladder dysfunction they are suffering from. Patients&#xD;
      suffering from an overactive bladder will receive antimuscarinic treatment in order to&#xD;
      prevent high urine storage and voiding pressures, that put the kidneys at risk.&#xD;
&#xD;
      Prior to the urologic examination, patients fulfilling inclusion criteria will be contacted.&#xD;
      If informed consent is given, cognitive function will be evaluated in both patient groups&#xD;
      using different standard neuropsychologic tests. The same neuropsychologic tests will be&#xD;
      repeated three months later. Evaluation will take place under standardized conditions (e.g.&#xD;
      time of day).&#xD;
&#xD;
      Furthermore,different factors influencing cognition, e.g. depression, pain, medication, will&#xD;
      be assessed at the beginning and end of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>d2 Test</measure>
    <time_frame>change from enrollement to 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>International Spinal Cord Injury Pain Basic Data Set</measure>
    <time_frame>day 0 and at 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory Score</measure>
    <time_frame>day 0 and at 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient characteristics</measure>
    <time_frame>day 0</time_frame>
    <description>age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>type of neurologic lower urinary tract dysfunction</measure>
    <time_frame>day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroop Test</measure>
    <time_frame>day 0 and at 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>California Verbal Learning Test</measure>
    <time_frame>day 0 and at 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Verbal Fluency Test according to Thurstone</measure>
    <time_frame>day 0 and at 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visuospatial performance</measure>
    <time_frame>day 0 and at 3 months</time_frame>
    <description>subtests from Wechsler Adult Intelligence Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>divided attention</measure>
    <time_frame>day 0 and at 3 months</time_frame>
    <description>subtests from test battery according to Zimmermann and Fimm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient characteristics</measure>
    <time_frame>day 0</time_frame>
    <description>sex</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient characteristics</measure>
    <time_frame>day 0</time_frame>
    <description>date of injury</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient characteristics</measure>
    <time_frame>day 0</time_frame>
    <description>tpe of accident</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient characteristics</measure>
    <time_frame>day 0</time_frame>
    <description>Glasgow Coma Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient characteristics</measure>
    <time_frame>day 0</time_frame>
    <description>lesion level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient characteristics</measure>
    <time_frame>day 0</time_frame>
    <description>completeness of injury</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient characteristics</measure>
    <time_frame>day 0</time_frame>
    <description>ASIA impairment score</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">32</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <condition>Spinal Cord Injuries</condition>
  <arm_group>
    <arm_group_label>antimuscarinic treatment</arm_group_label>
    <description>antimuscarinic treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no antimuscarinic treatment (control)</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>antimuscarinic treatment</intervention_name>
    <arm_group_label>antimuscarinic treatment</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with acute (4-8 week post-injury) traumatic spinal cord injury during first&#xD;
        rehabilitation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  acute traumatic spinal cord injury&#xD;
&#xD;
          -  primary rehabilitation / in-house patient&#xD;
&#xD;
          -  18-65 years of age&#xD;
&#xD;
          -  treatment group: indication for antimuscarinic treatment (oxybutynin, tolterodine&#xD;
&#xD;
          -  willingness and motivation to participate in study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  lesion level above C4&#xD;
&#xD;
          -  traumatic brain injury (initial Glasgow Coma Score &lt; 13)&#xD;
&#xD;
          -  pre-existing dementia&#xD;
&#xD;
          -  pre-existing impaired cognitive function&#xD;
&#xD;
          -  previous antimuscarinic treatment&#xD;
&#xD;
          -  treatment group: antimuscarinic treatment other than oxybutynin, tolterodine&#xD;
&#xD;
          -  acute psychologic disorders, diseases, schizophrenia&#xD;
&#xD;
          -  alcohol abuse, consumption of illegal drugs (incl. marijuana)&#xD;
&#xD;
          -  moderate to severe depression (Beck Depression Inventory Score &gt; 18)&#xD;
&#xD;
          -  moderate to severe pain (International Spinal Cord Injury Pain Basic Data Set)&#xD;
&#xD;
          -  progressive disease&#xD;
&#xD;
          -  tricyclic antidepressant&#xD;
&#xD;
          -  color blindness, impaired sight, blindness&#xD;
&#xD;
          -  insufficient German language skills&#xD;
&#xD;
          -  no informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JÃ¼rgen Pannek, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Swiss Paraplegic Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Swiss Paraplegic Centre</name>
      <address>
        <city>Nottwil</city>
        <state>LU</state>
        <zip>6207</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>May 10, 2012</study_first_submitted>
  <study_first_submitted_qc>May 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2012</study_first_posted>
  <last_update_submitted>November 16, 2015</last_update_submitted>
  <last_update_submitted_qc>November 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mild Cognitive Impairment</keyword>
  <keyword>Muscarinic Antagonists</keyword>
  <keyword>Spinal Cord Injuries</keyword>
  <keyword>Urinary Bladder, Neurogenic</keyword>
  <keyword>Urinary Bladder, Overactive</keyword>
  <keyword>Overactive Detrusor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscarinic Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

